167 related articles for article (PubMed ID: 19568883)
1. Molecular biology of malignant mesothelioma.
Sekido Y
Environ Health Prev Med; 2008 Mar; 13(2):65-70. PubMed ID: 19568883
[TBL] [Abstract][Full Text] [Related]
2. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells.
Sekido Y
Cancer Sci; 2010 Jan; 101(1):1-6. PubMed ID: 19793348
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
[TBL] [Abstract][Full Text] [Related]
4. A mouse model recapitulating molecular features of human mesothelioma.
Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
[TBL] [Abstract][Full Text] [Related]
5. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
Lecomte C; Andujar P; Renier A; Kheuang L; Abramowski V; Mellottee L; Fleury-Feith J; Zucman-Rossi J; Giovannini M; Jaurand MC
Cell Cycle; 2005 Dec; 4(12):1862-9. PubMed ID: 16319530
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the p16(INK4) locus in human malignant mesothelial tumors.
Hirao T; Bueno R; Chen CJ; Gordon GJ; Heilig E; Kelsey KT
Carcinogenesis; 2002 Jul; 23(7):1127-30. PubMed ID: 12117769
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular genetic changes in malignant mesothelioma.
Musti M; Kettunen E; Dragonieri S; Lindholm P; Cavone D; Serio G; Knuutila S
Cancer Genet Cytogenet; 2006 Oct; 170(1):9-15. PubMed ID: 16965949
[TBL] [Abstract][Full Text] [Related]
8. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
Murthy SS; Testa JR
J Cell Physiol; 1999 Aug; 180(2):150-7. PubMed ID: 10395284
[TBL] [Abstract][Full Text] [Related]
9. Advances in the molecular biology of malignant mesothelioma.
Toyooka S; Kishimoto T; Date H
Acta Med Okayama; 2008 Feb; 62(1):1-7. PubMed ID: 18323865
[TBL] [Abstract][Full Text] [Related]
10. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.
Altomare DA; Menges CW; Pei J; Zhang L; Skele-Stump KL; Carbone M; Kane AB; Testa JR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3420-5. PubMed ID: 19223589
[TBL] [Abstract][Full Text] [Related]
11. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
12. The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma.
de Assis LV; Locatelli J; Isoldi MC
Biochim Biophys Acta; 2014 Apr; 1845(2):232-47. PubMed ID: 24491449
[TBL] [Abstract][Full Text] [Related]
13. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
14. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO).
Dopp E; Poser I; Papp T
Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL271-7. PubMed ID: 12643444
[TBL] [Abstract][Full Text] [Related]
15. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
16. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
Bianchi AB; Mitsunaga SI; Cheng JQ; Klein WM; Jhanwar SC; Seizinger B; Kley N; Klein-Szanto AJ; Testa JR
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10854-8. PubMed ID: 7479897
[TBL] [Abstract][Full Text] [Related]
17. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E
Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients.
Kitamura F; Araki S; Suzuki Y; Yokoyama K; Tanigawa T; Iwasaki R
Ind Health; 2002 Apr; 40(2):175-81. PubMed ID: 12064559
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
